Pfizer chief sets out the potential implications of 'Most Favored Nation' pricing

In response to a question about the risk of removing products from reimbursement in some countries to protect the US market, Pfizer Chief Executive and PhRMA Chair Dr Albert Bourla said, "I think yes." …